Efficacy and safety of adding once‐weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD‐CHN3): A randomized, double‐blind, placebo‐controlled, phase III trial
Article in Diabetes Obesity and Metabolism (September 2023)